European Neurology · 2008 · 10 citations · 0 references
MedicineNeurologyPharmacotherapyDosage Form DesignNeuropharmacologyPsychopharmacologyDopaminergic PharmacologyNeurodegenerative Disease PharmacotherapyParkinson DiseaseParkinsonian DisordersDopaminergic Therapy ManagementParkinson's Disease PharmacotherapyParkinson’s Disease PharmacotherapyParkinson’s Disease Treatment
In this open study patients with advanced Parkinson's disease, who experienced pronounced fluctuations in symptoms while on standard L-dopa, were switched from Madopar/Sinemet to Madopar HBS. The dosage was adjusted until optimal response was obtained. The effect was unsatisfactory in 4 cases and side effects intervened in another 2. The remaining 16 patients exhibited substantial and frequently significant improvements with regard to both akinetic and dyskinetic phenomena. L-Dopa dosage was increased in all cases, and addition of standard L-dopa was required in one third of the cases. These benefits continued in the majority of patients.